Compare
Turn Therapeutics Inc. vs Imunon, Inc. vs NewcelX Ltd. vs NRX Pharmaceuticals, Inc.
| Latest fiscal year | Turn Therapeutics Inc. TTRX | Imunon, Inc. IMNN | NewcelX Ltd. NCEL | NRX Pharmaceuticals, Inc. NRXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $1.45M |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | 65.1% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$3.19M | -$14.50M | -$8.30M | -$28.62M |
| EPS (Diluted) | -$0.12 | -$6.83 | $2.16 | n/a |
| Operating cash flow | -$2.56M | -$13.90M | -$2.77M | -$14.11M |
| Free cash flow | n/a | -$14.18M | -$2.77M | n/a |
| Cash & equivalents | $4.03M | $8.78M | $2.20M | $7.80M |
| Total assets | $12.16M | $12.29M | $11.45M | $12.96M |
| Total liabilities | $7.48M | $5.23M | $4.20M | $28.89M |
| Shareholders' equity | $4.69M | $7.06M | $7.25M | -$15.94M |
| Return on year-end equity | -68.2% | -205.3% | -114.5% | n/a |
| Shares outstanding | 29.45M | 3.42M | 4.80M | 31.73M |
Revenue, most recent five fiscal years
| Fiscal year | Turn Therapeutics Inc. | Imunon, Inc. | NewcelX Ltd. | NRX Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $500.0K Ended 2022-12-31 | n/a | $1.45M Ended 2025-12-31 |
| 1 year earlier | n/a | $500.0K Ended 2021-12-31 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $500.0K Ended 2020-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $500.0K Ended 2019-12-31 | n/a | n/a |
| 4 years earlier | n/a | $500.0K Ended 2018-12-31 | n/a | n/a |